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2012 were analyzed for their ASMR ratings. Analysis were conducted to identify
new trends and compare them for products based on their indications, compara-
tors and launch timing. RESULTS: Analysis of 2011-2012 assessments by TC shows
that majority of products (73%) received an ASMR rating of IV (minor improve-
ment). Approximately 27% of the products received an ASMR rating of III and V. A
new trend in TC’s assessment is the assignment of two ASMR ratings for one
product for different subgroups or patient line of treatment. During last one year 3
out of 11 products received two ASMR ratings. None of the products received ASMR
ratings of I and II. The products that received ASMR rating of V (no improvement)
were indicated for cardiovascular, epilepsy and bone metastases. All assessments
included analysis of intervention’s data versus one or more comparators.
CONCLUSIONS: France TC’s assessments trends show need for robust comparative
effectiveness data to obtain better ASMR ratings, which affects both pricing and
market access of new products. Future products would need subgroup analysis to
obtain high ASMR ratings for all patient populations.
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OBJECTIVES: Safe endoscope reprocessing requires meticulous adherence to
guidelines. Human error is a principal cause of deficient reprocessing. Approaches
vary from fully manual processes, to semi-automatic reprocessors, or fully auto-
mated cleaner and reprocessors. We assessed key issues in endoscope reprocess-
ing related to guideline adherence, health and resource outcomes and staff burden.
METHODS: PubMed was searched from January 1, 2007 to March 7, 2012. Search
terms: ((Endoscope OR endoscopy) AND (Reprocessing OR Cleaning OR Disinfection
OR Biofilms)). Abstracts were screened by 2 independent reviewers and included
according to research areas: 1) adherence to endoscope reprocessing guidelines; 2)
endoscopy related adverse contamination outcomes and; and 3) adverse effects of
endoscope reprocessing on staff. Reference lists of key papers were searched.
RESULTS: Six studies assessed guideline adherence. Non-adherence levels varied
considerably with a trend for less developed health care systems to have poorer
adherence. For study question 2, 19 articles reported 7 infection outbreaks, 6 pseu-
do-outbreaks and 4 toxic reactions related to endoscope procedures. The majority
of events could have been prevented if standard reprocessing practices were fol-
lowed. Eight studies (1 each from Canada, Japan and US and 5 from Europe) con-
sidered the impact of device reprocessing on staff health, time, or the associated
costs. Two studies reported that manual reprocessing had a significant health
impact on staff including respiratory ailments and physical discomfort. One study
reported that in a single hospital reprocessing time was 6.2 hours longer per day
with manual vs. automated procedures; this had a resultant impact on costs.
CONCLUSIONS: Effective reprocessing is vital to ensure safe use of endoscopes.
Guideline adherence is variable, and poor standards can lead to adverse outcomes.
Manual reprocessing is associated with considerable health burdens for staff. Au-
tomated reprocessing could improve guideline adherence and reduce the burden
on staff, as well as reduce costs. Further studies in this area are warranted.
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OBJECTIVES: Our goal was to analyze the Hungarian drug reimbursement deci-
sions - through the reimbursement of new molecular entities (NME) in the period of
2007-2011. METHODS: NME’s were collected from the official drug reimbursement
list published monthly on the website of the National Health Insurance Fund of
Hungary (NHIF). Drugs with hospital reimbursement were excluded from the anal-
ysis, as their reimbursement process differs. There are two ways to reimburse an
Rx NME in Hungary: Route A: NHIF is the final decision maker, there is no need for
legislation change. Route B: In case of e.g. new restricted indication or a new ATC4
level of a given NME, the final decison makers are, Ministry of Health & previously
Ministry of Finance, currently Ministry of Economy. In these latest cases a minis-
terial decree is published, containing the reimbursement list of NME’s. RESULTS:
Within the observed period 86 new molecules gained reimbursement from the
Drug Budget. The most NME’s gained reimbursement in 2008 (23 NME’s). A total of
33% of the products belong to two ATC categories: A and L, and most of NME’s (40%)
are fully reimbursed. 34 % of the products needed Route B to gain reimbursement.
More than half of these products (16 molecules) gained reimbursement in 2008,
however no such decision was made in 2009 and only 3 molecules have been
reimbursed in 2010 and 2011, respectively! CONCLUSIONS: The number of reim-
bursement decisions made through Route A didn’t change in this 5-year period.
However the number of Route B reimbursement decision dropped significantly
from 2008, resulting a significant market access delays for the Hungarian patients.
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OBJECTIVES: To suggest a new classification of different pharmaceutical payment
methods and to analyze the implementation of those methods in different health
care settings of IQ Partners’ Countries. This division will facilitate the comparative
analysis of the impact of different payment methods on health care costs, effi-
ciency, quality and equity. METHODS: Data on pharmaceutical payment methods
were obtained through a review of the available literature. The search included
relevant economic and medical databases, journals and books, conference mate-
rials and other projects. Different examples of payment methods were extracted
from publications (95 positions) and classified. The implementation of those meth-
ods in different countries was also described. RESULTS: The practical classification
of pharmaceutical payment methods was based on two main categories: tradi-
tional (well established and widely used) and innovative (implemented in recent
years, depending on the country). A sub-classification was also outlined, related to
the regulatory mechanisms of the methods in question: market driven, adminis-
trative regulations and market mechanisms with administrative settings (mixed).
The traditional payment methods and schemes include: “free” prices, fixed prices,
flexible prices, fixed budget, reference pricing, margins, rebate agreements, bonus
agreements and patient’s co-payment. The innovative payment methods include
price volume agreements, cross-product agreements, risk-sharing, value-based
pricing, framework agreements, cost-plus pricing, patient access schemes, portfo-
lio deals, one price per patient, disease management. The second group was sub-
sequently introduced in selected countries, including UK and US with a trend to be
used in others countries (e.g. Poland). CONCLUSIONS: Innovative payment meth-
ods allow risk-sharing both related to costs and outcomes creating an additional
platform for a dialogue between authorities and producers.
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OBJECTIVES: Point-of-care (POC) testing, also called near-patient, bedside, alter-
nate-site or decentralized testing, includes all in vitro testing where conduct and
analysis occurs outside the laboratory setting (e.g., physician office, at home), and
within a short time period while the patient waits. Development of POC diagnostic
tests (POCTs) has been on the rise in recent years and promises to reduce health
care costs by reducing utilization of costly centralized laboratory-based testing, the
need for follow-up office visits by patients to review laboratory test results, and/or
sample shipment and storage. Despite the potential of POC testing, health systems
and payers have been slow to adopt and reimburse such tests. To examine key
issues influencing POCT reimbursement and market access, global health technol-
ogy assessments (HTAs) were evaluated to identify stakeholder concerns contrib-
uting to the slow penetration of POCTs. METHODS: Published global POCT HTA
recommendations were identified and reviewed to provide insights into criteria
scrutinized and concerns registered by HTA agencies. RESULTS: POCT HTAs iden-
tified included those for cardiovascular, endocrine, oncologic, pulmonary/allergic,
and infectious diseases, and those informing therapeutic or illicit drugs. In assess-
ing POCTs, agencies scrutinized criteria generally fitting into four categories of
evidence including Testing Logistics, Clinical Validity/Utility, Economic Value/
Cost, and Ethical Concerns. For Testing Logistics: agencies scrutinized test turn-
around time, platform accessibility and current penetration, required sample size,
specimen collection and transport, and result/quality tracking; Clinical Validity/
Utility: test performance (e.g., sensitivity, specificity, false positives/negatives) and
agreement with/efficacy relative to lab-based tests, and impact on provider deci-
sion-making/patient outcomes; Economic Value/Cost: cost-offsets, cost-effective-
ness, and cost-minimization; Ethical Concerns: implications of erroneous results
and privacy issues. CONCLUSIONS: POC testing approaches hold potential to re-
duce health care costs while maintaining or improving patient outcomes. Evidence
required to support POCT HTA should be considered during development of new
POCTs to increase the likelihood of achieving reimbursement and market access.
PHP39
EXPLANING DIFFERENCES IN EU5 MARKET PENETRATION LEVELS AND RATES
OF BIOSIMILARS: THE CASE OF EPOETINE, GRANULOCYTE-COLONY
STIMULATING FACTOR, AND GROWTH HORMONES
Frenzel A1, Schmidt N2, Grahl J3
1IMS Health, Frankfurt/Main, Germany, 2Johannes Gutenberg-University Mainz, Mainz,
Germany, 3Johannes Gutenberg-Universität Mainz, Mainz, Germany
OBJECTIVES: Biosimilars are off-patent biologicals that shall provide cost savings
and greater accessibility to biopharmaceuticals. Within the next five years, several
top-selling biologics like Herceptin, Enbrel, Humalog, are due to loose patent pro-
tection. This opens business opportunities, but little is known about the biosimilar
market. The main biosimilar product classes are biosimilars of Epoetine (EPO),
Granulocyte-Colony Stimulating Factor (G-CSF) and Growth Hormoes (GH). Market
penetration levels for these biosimilars differ substantially across Germany,
France, UK, Italy and Spain (EU5). Literature does not provide an stringent expla-
nation for these differences.We attempt to fill this gap by explaining the diverse
levels of biosimilar uptake. METHODS: We model the diffusion process of biosimi-
lars in pharmaceutical markets with a Bass diffusion model. Model parameters are
estimated from IMS Health sales data on three Biosimilar classes in the EU5 coun-
tries. The estimated model parameters differ across countries and products. To
explain these differences, we conduct several expert interviews.The theoretical
lense guiding the interviews is Rogers theory of innovations and how properties of
an innovation influence diffusion. RESULTS: We find that Germany and France
account for approximately half the biosimilars market by value and a 34% and 17%
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